Showing 1441-1450 of 2910 results for "".
- Clinical Trial of Rimegepant for Trigeminal Neuralgia Enrolls First Participanthttps://practicalneurology.com/news/clinical-trial-of-rimegepant-for-trigeminal-neuralgia-enrolls-first-participant/2468946/The first patient has been enrolled in a double-blind placebo-controlled clinical trial (NCT03941834) to assess rimegepant (Biohaven Pharmaceuticals, New Haven, CT)—a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist—for treatment of trigeminal neuralgia refrac
- OnabotulinumtoxinA Approved for Treatment of Children with Upper Limb Spasticityhttps://practicalneurology.com/news/onabotulinumtoxina-approved-for-treatment-of-children-with-upper-limb-spasticity/2468936/The Food and Drug Administration (FDA) has approved a new indication for onabotulinumtoxinA (Botox; Allergan, Madison, NJ)—treatment of upper limb spasticity in children, age 2 to 17 years. The decision came after a 6-month priority review, which istypically granted to therapies with potent
- Nusinersen Efficacy for Later-Onset Spinal Muscular Atrophy Types II and IIIhttps://practicalneurology.com/news/nusinersen-efficacy-for-later-onset-spinal-muscular-atrophy-types-ii-and-iii/2468883/April 24, 2019—Children with later-onset spinal muscular atrophy (SMA) types II and III treated with nusinersen (Spinraza; Biogen, Cambridge MA) had motor function improvement and disease stabilization over a 3-year period. Of the children with SMA II, 78% (7 of 9) had clinically meaningful
- Multiple Sclerosis Prevalence May Be Twice As High as Previously Thoughthttps://practicalneurology.com/news/multiple-sclerosis-prevalence-may-be-twice-as-high-as-previously-thought/2468830/A study published in the journal Neurology suggests prevalence of multiple sclerosis (MS) in the US is 913,925—more than twice the previous estimate of 400,000 people in
- FDA Recalls Software Used with Surgical Navigation Systemhttps://practicalneurology.com/news/fda-grants-breakthrough-device-designation-for-alzheimers-disease-screening-test/2468857/Medtronic has recalled software used during biopsy procedures due to reports that the products—Synergy Cranial Software and StealthStation S7 Cranial Software—provided incorrect information that could result in serious or life-threatening harm to patients. The FDA has id
- Stem-Cell Transplants Delayed Disease Progression of Multiple Sclerosishttps://practicalneurology.com/news/stem-cell-transplants-delayed-disease-progression-of-multiple-sclerosis/2468861/January 25, 2019—As published in JAMA, interim results of the phase 2 MIST trial (NCT00273364) show that stem-cell treatment resulted in a signific
- FDA Approves Generic Vigabatrin for Complex Partial Seizureshttps://practicalneurology.com/news/fda-approves-generic-vigabatrin-for-complex-partial-seizures/2468865/January 21, 2019—The Food and Drug Administration (FDA) has approved generic vigabatrin 500 mg tablets for adjunctive treatment of patients with complex partial seizures, age 10 years and older, who have not responded adequately to other treatments. “We know there has been
- New Study Will Evaluate Smart Watch Technology for Help in Preventing Strokeshttps://practicalneurology.com/news/new-study-will-evaluate-smart-watch-technology-for-help-in-preventing-strokes/2468864/January 21, 2019—A new study will analyze the impact of a smart watch (Apple, Cupertino, CA) on early detection and diagnosis of atrial fibrillation (AFib) and the potential to prevent stroke. The large-scale research will start later this year in the US and will be a pragmatic, randomized,
- David Weisman, MDhttps://practicalneurology.com/profiles/david-weisman-md/Ld1dDw/Dr. David Weisman received a BA in philosophy from Franklin and Marshall College, then an MD from Pennsylvania State College of Medicine. After an internship at St. Mary's Hospital in San Francisco, he completed neurology residency at Yale, where he served as Chief resident. He then went to Univers…
- David Porter, MDhttps://practicalneurology.com/profiles/david-porter-md/7v0PzO/Dr. David Porter is a professor of medicine at the University of Pennsylvania School of Medicine and director of stem cell transplantation and immunotherapy at the Hospital of the University of Pennsylvania in Philadelphia. He is a graduate of the University of Rochester and earned a medical deg…